Dr. Jan Drappatz
Neurology (Neurology Physician)
5115 Centre Ave, Upmc, Hillman Cancer Center
Pittsburgh, PA 15232
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 150
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
PA license 443436
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Presbyterian Shadyside Pittsburgh, PA
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- UPMC PAssavant Pittsburgh, PA
- UPMC St Margaret Pittsburgh, PA
- Penn Highlands Elk Saint Marys, PA
Medical groups
- University of Pittsburgh Physicians (4,236 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 150
- Services billed
- 424
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 134 | 57 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 63 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 62 | 45 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 31 | 24 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 30 | 29 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 16 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 7 payments worth $13,069 in total to this clinician.
| Servier Pharmaceuticals LLC | $13,000 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $69.28 |
| Consulting Fee | $12,806 |
|---|---|
| Travel and Lodging | $150 |
| Food and Beverage | $113 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Servier Pharmaceuticals LLC Dec 5, 2025 | Consulting Fee Voranigo · Oncology | $12,750 |
| Servier Pharmaceuticals LLC Nov 11, 2025 | Travel and Lodging Voranigo · Oncology · travel to Las Vegas, NV | $72.00 |
| Servier Pharmaceuticals LLC Nov 12, 2025 | Consulting Fee Voranigo · Oncology | $56.14 |
| Servier Pharmaceuticals LLC Nov 11, 2025 | Travel and Lodging Voranigo · Oncology · travel to Las Vegas, NV | $39.90 |
| Servier Pharmaceuticals LLC Nov 11, 2025 | Travel and Lodging Voranigo · Oncology · travel to Las Vegas, NV | $38.51 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $190,740 in research payments for these studies, mostly to the institutions running them.
- A Phase I Multicentre Study to Assess the Safety Tolerability and Pharmacokinetics of Ascending Doses of AZD1390 in Combination with Radiation Therapy in Patients with Glioblastoma Multiforme and Brain Metastases from…
AstraZeneca Pharmaceuticals LP - Study of vorasidenib, AG-881, in participants with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation, indigo
Servier Bioinnovation - A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single …
Novartis Pharmaceuticals Corporation - EF-41/?KEYNOTE D58: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune (TTFields, 200 kHz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune Concomitant With Maintenance Te…
Novocure GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.